What exactly are “histamine production” biosynthesis claims in an USPTO patent application?
Patent applications that mention histamine production biosynthesis typically claim one or more steps in a biological pathway that generates histamine, or systems/methods that drive histamine production. In practice, “biosynthesis” claims often map to enzyme-driven steps (for example, converting histidine toward histamine via histidine decarboxylase) and may be written as:
- A method of producing histamine in a biological system (e.g., a microorganism or engineered cell).
- Genetic or protein-based claims tied to enzymes in the histamine-producing pathway.
- Claims covering engineered strains, vectors, or edited genomes that increase histamine output.
- Claims about culturing conditions or fermentation processes that support histamine biosynthesis.
These are usually framed as “A method comprising…” or “An engineered microorganism comprising…” where the “biosynthesis” portion is the claimed biological activity that results in histamine generation.
Which histamine biosynthesis steps are commonly claimed?
When claims target histamine biosynthesis, they usually focus on the pathway components that directly control flux to histamine, such as:
- Enzymes that convert precursor amino acids toward histamine (commonly the decarboxylation step associated with histidine decarboxylase).
- Genetic elements that express or upregulate the relevant enzyme(s).
- Host organisms designed or selected to carry out those steps efficiently.
Some applications also claim broader upstream control (e.g., precursor supply), but the tighter claims tend to center on the conversion step(s) that produce histamine.
How are “histamine production” claims likely to be written (US patent claim style)?
USPTO filings typically use claim language that defines both (1) what is built or selected and (2) what is done to produce histamine. Common patterns include:
- Product-by-process style: an engineered cell or microorganism characterized by how it produces histamine.
- Method claims: culturing or fermenting an organism under defined conditions to produce histamine.
- Compositions: formulations containing histamine produced by a claimed method (sometimes with downstream purification steps).
- Molecular claims: engineered nucleic acids and/or proteins that enable histamine biosynthesis.
What USPTO search terms work best for finding these applications?
If you’re searching USPTO records for applications with histamine production biosynthesis claims, you usually get better results by mixing pathway/functional terms with patent-claim terms. Queries commonly include combinations like:
- “histamine” AND “biosynthesis”
- “histidine decarboxylase” AND histamine
- “engineered microorganism” AND histamine
- “histidine” AND “decarboxylase” AND histamine
- “fermentation” AND histamine production
- “nucleic acid” OR “vector” AND histidine decarboxylase (and/or histamine)
Adding claim-style words (method, engineered, comprising, nucleic acid, vector, recombinant) can help narrow results to claim-heavy filings.
Are histamine biosynthesis claims more likely to be in biotech/industrial fermentation than therapeutics?
Historically, many “histamine production” claim sets are tied to industrial biology (fermentation/biocatalysis) because the claims can be satisfied by culturing engineered organisms and measuring histamine output. But there are also bioengineering and cell biology contexts where histamine production matters (for example, modulating histamine-generating pathways in cells). The wording you see (“engineered microorganism,” “culturing,” “fermenting,” “production”) is a strong signal of which area the claims target.
What pitfalls show up when reading these claims?
A few recurring issues affect how useful the claims are for understanding “histamine production”:
- Some filings claim the enzyme/genetic construct but not the full process of production, so the “histamine output” may be implicit rather than an explicit process step.
- Other filings claim a downstream purification/assay more than the biosynthetic pathway itself.
- “Histamine” can appear in broader immunology claims (histamine signaling) where the histamine is not produced by the claimed biosynthetic pathway. You need to check whether the claims explicitly require production/biosynthesis versus merely referencing histamine in assays or compositions.
What I need from you to identify the exact claims in USPTO applications
Your question is broad (“Uspto patent application histamine production biosynthesis claims”). To extract or summarize specific claim language, I need one of the following:
- The USPTO application number (or patent number), or
- The assignee/company name, or
- A link to the application, or
- Published application numbers (USYYYY/NNNNNNN), or
- The text of the claims you want interpreted.
Send any one of those, and I can point to the exact claim elements that cover histamine biosynthesis (e.g., the enzyme/genetic step, the engineered host, and the culturing/production conditions).
Sources
No USPTO documents or application text were provided, so there are no sources to cite.